

**DI-*t*-BUTYL *N,N*-DIETHYLPHOSPHORAMIDITE AND DIBENZYL *N,N*-DIETHYLPHOSPHORAMIDITE.  
 HIGHLY REACTIVE REAGENTS FOR THE 'PHOSPHITE-TRIESTER'  
 PHOSPHORYLATION OF SERINE-CONTAINING PEPTIDES**


John W. Perich and R. B. Johns\*

Department of Organic Chemistry, University of Melbourne, Parkville 3052,  
 Victoria, Australia.

**ABSTRACT:** *Di-t-butyl N,N-diethylphosphoramidite and dibenzyl N,N-diethylphosphoramidite were found to be highly reactive reagents for the efficient 'phosphite-triester' phosphorylation of protected serine derivatives (Boc-Ser-ONBzl), protected serine-containing peptides and resin-bound protected serine-containing peptides.*

As an alternative to the use of dibenzyl and di-*t*-butyl phosphorohalidates for the phosphorylation of alcohols,<sup>1-3</sup> our recent studies have concentrated on the use of dialkyl *N,N*-diethylphosphoramidites for the efficient phosphorylation of alcohols and hydroxy-containing biomolecules. In particular, we have concentrated on the use of benzyl and *t*-butyl groups for temporary phosphate protection on account of the facile hydrogenolytic<sup>1</sup> or acidolytic<sup>3</sup> cleavage of these phosphate protecting groups. From these studies, we have demonstrated that the phosphoramidite reagents, di-*t*-butyl *N,N*-diethylphosphoramidite **1a** and dibenzyl *N,N*-diethylphosphoramidite **1b**, are stable yet highly reactive reagents for the 'phosphite-triester' phosphorylation of simple alkyl alcohols [(i) (RO)<sub>2</sub>PNet<sub>2</sub> (R = Bu<sup>t</sup> or Bzl)/1H-tetrazole, (ii) mCPBA] and give the respective di-*t*-butyl and dibenzyl phosphorotriesters in 90-99% yields (Scheme 1).<sup>4,5</sup> In this letter, we report the use of


Scheme 1.



**1a** and **1b** for the efficient 'phosphite-triester' phosphorylation of a protected serine and tyrosine derivative, a protected serine-containing peptide and a resin-bound protected serine-containing peptide.


In the first instance, the 'phosphite-triester' phosphorylation procedure was found to be useful for the phosphorylation of simple protected serine derivatives, 1a or 1b/1H-tetrazole treatment of Boc-Ser-ONBzl **2** followed by *in situ* non-nucleophilic oxidation (mCPBA) affording Boc-Ser(PO<sub>3</sub>Bu<sup>t</sup>)<sub>2</sub>-ONBzl **3a** and Boc-Ser(PO<sub>3</sub>Bzl)<sub>2</sub>-ONBzl **3b** in 92 and 98% yields respectively (Scheme 2). Products **3a** and **3b** gave typical <sup>31</sup>P NMR chemical shift values of -9.6 and +0.8 ppm respectively and their structures were confirmed by the observation of phosphorus-coupled doublet signals for the C<sub>α</sub> and C<sub>β</sub> carbons of the seryl residue (J<sub>PC</sub> 5.8 Hz) in their <sup>13</sup>C NMR spectra.

Scheme 2.




Alternatively, this procedure can also be applied to the phosphorylation of protected tyrosine derivatives, the phosphitylation of Boc-Tyr-ONBzl using 1b/1H-tetrazole followed by mCPBA oxidation giving Boc-Tyr(PO<sub>3</sub>Bzl)<sub>2</sub>-ONBzl **5** in near-quantitative yield (Scheme 3). This procedure is far superior to other reported procedures in that it does not require pre-generation of the sodium phenoxide<sup>7</sup> or suffer from the low reactivity of the dibenzyl hydrogen phosphonate/carbon tetrachloride phosphorylation procedure.<sup>8</sup>

Scheme 3.




In addition, the 'phosphite-triester' phosphorylation procedure was also extended to the phosphorylation of a protected serine tripeptide Boc-Glu(OBu<sup>t</sup>)-Ser-Leu-OBu<sup>t</sup>. The synthesis of the serine-containing peptide **10** was accomplished by the solution phase incorporation of Fmoc-Ser(Bu<sup>t</sup>)-OH using the mixed anhydride coupling procedure, the use of 10% diethylamine/DMP<sup>9</sup> for removal of the Fmoc group from dipeptide **7** and final hydrogenolytic removal of the seryl benzyl ether group. The phosphorylation of **10** in dry THF using either **1a** or **1b** proceeded smoothly and gave Boc-Glu(OBu<sup>t</sup>)-Ser(PO<sub>3</sub>Bu<sup>t</sup>)<sub>2</sub>-Leu-OBu<sup>t</sup> **11a** or Boc-Glu(OBu<sup>t</sup>)-Ser(PO<sub>3</sub>Bzl)<sub>2</sub>-Leu-OBu<sup>t</sup> **11b** in 95 and 96% yields respectively after purification. The structural characterization of these products was readily established by their <sup>13</sup>C NMR spectra<sup>10,11</sup> and <sup>31</sup>P NMR spectra, <sup>31</sup>P NMR values of -9.2 and -0.8 ppm being observed for **11a** and **11b** respectively. Subsequent hydrogenolytic or acidolytic treatment of **11a** and **11b** respectively in 40% TFA/AcOH effected ready removal of the protecting groups and gave the pSer-tripeptide CF<sub>3</sub>CO<sub>2</sub>H-H-Glu-Ser(PO<sub>3</sub>H<sub>2</sub>)-Leu-OH in quantitative yield. Structural confirmation and the purity of **12** was established from its <sup>31</sup>P NMR spectrum (+0.10 ppm), its

$^{13}\text{C}$  NMR spectrum and from its FAB-mass spectrum (Ar, +ve mode,  $m/z$  348,  $\text{M}^+$ ). Although P-Ser-containing peptides have previously been prepared via the use of temporary benzyl phosphate protection, the synthesis of **12** from **11a** represents the first P-Ser-peptide that has been prepared via the use of *t*-butyl phosphate protection. A feature in the use of *t*-butyl phosphate protection is that the di-*t*-butyl phosphotriester functionality is readily deprotected with the use of mild acid treatments and that the isolation of the P-Ser-containing peptide is simple and effected in a metal-free ( $\text{Ca}^{2+}$ ) environment.



- (i)  $\text{NH}_4\text{Cl}$  (1 eq) then  $\text{NH}_4\text{Cl}/\text{IBCF}$  ( $-20^\circ$ , 2h), (ii) 10%  $\text{Et}_2\text{NH}/\text{DMF}$  ( $20^\circ$ , 2h)  
 (iii)  $\text{NH}_4\text{Cl}/\text{IBCF}$  ( $-20^\circ$ , 2 h), (iv)  $\text{H}_2$ -Pd/C, AcOH.  
 (v)  $(\text{RO})_2\text{PNET}_2$  (R = Bu<sup>t</sup> or Bzl)/1H-tetrazole (10 min), then mCPBA ( $-40^\circ$ , 5 min),  
 (vi) 40% TFA/AcOH (R = Bu<sup>t</sup>) or  $\text{H}_2$ -Pd/C, 40% TFA/AcOH (R = Bzl).

In continuation of this study, both **1a** and **1b** were also suitable for the 'phosphite-triester' phosphorylation of the resin-bound seryl-containing tripeptide, Z-Glu(OBzl)-Ser-Leu-P (P = 1% cross-linked polystyrene resin). The resin-bound tripeptide was prepared using Merrifield 1% cross-linked polystyrene resin as the peptide support, the incorporation of Fmoc-Ser(Bu<sup>t</sup>)-OH into peptide synthesis (DCC/HOBt) using the Merrifield peptide synthesis protocol, 20% piperidine/DMF for removal of the Fmoc group from **15** and 90% TFA/ $\text{CH}_2\text{Cl}_2$  for acidolytic removal of the seryl *t*-butyl ether group. The phosphorylation of **18** using either **1a** or **1b** proceeded quantitatively and was confirmed by analysis of the  $^{13}\text{C}$  NMR and  $^{31}\text{P}$  NMR spectra obtained from the peptide-resins swollen in  $\text{CDCl}_3$ , these latter spectra giving typical chemical shift values for **19a** and **19b** of  $-9.2$  and  $-0.3$  ppm respectively. In the case of **19a**, further treatment of the peptide-resin with 10% TFA/ $\text{CH}_2\text{Cl}_2$  readily removed the *t*-butyl groups and gave the protected resin-bound Ser( $\text{PO}_3\text{H}_2$ )-containing peptide **20**, the  $^{31}\text{P}$  NMR spectrum of **20** showing a broad single peak at 0.0 ppm. These results clearly show that the 'phosphite-triester' phosphorylation procedure can be extended to resin-bound serine-containing peptides and, in the case of *t*-butyl protection, the di-*t*-butyl phosphates can be readily converted to their mono-alkyl phosphates.



(i) DCC/HOBt (20°, 3 h), (ii) 20% piperidine/DMF (1x3 min, 1x7 min),  
 (iii) 90% TFA/CH<sub>2</sub>Cl<sub>2</sub> (60 min), (iv) (RO)<sub>2</sub>PNET<sub>2</sub> (R = Bu<sup>t</sup> or Bzl)/1H-tetrazole (15 min) then  
 mCPBA (10 min), (v) 10% TFA/CH<sub>2</sub>Cl<sub>2</sub> (R = Bu<sup>t</sup>) (30 min).

This work clearly demonstrates that **1a** and **1b** are ideal reagents for the 'phosphite-triester' phosphorylation of protected serine derivatives and the phosphorylation of serine-containing peptides. In view of the ready removal of *t*-butyl and benzyl phosphate groups, we consider the phosphoramidite-based phosphorylation procedure described here will find wide application in the general phosphorylation of other simple serine-containing peptides and hydroxy-containing biomolecules.

**ACKNOWLEDGEMENT** : The authors acknowledge the support of the Australian Wool Corporation.

#### REFERENCES AND NOTES

- Folsch, G., *Sven. Kem. Tidskr.*, **79**, 38, (1967).
- Khwaja, T. A., Reese, C. B. and Stewart, J. C. M., *J. Chem. Soc. (C)*, 2092, (1970).
- Gajda, T. and Zwierzak, A., *Synthesis*, 623, (1978).
- Perich, J. W. and Johns, R. B., *Tetrahedron Lett.*, 101, (1987).
- Perich, J. W. and Johns, R. B., *Synthesis*, 142, (1988).
- <sup>13</sup>C NMR (CDCl<sub>3</sub>) **5**: δ 28.3, 37.3, 55.1, 65.4, 70.0 (d, 4.4 Hz), 80.0, 120.2 (d, 5.9 Hz), 123.7, 128.0, 128.5, 128.7, 130.6, 133.3, 135.4 (d, 7.3 Hz), 142.6, 147.6, 149.6 (d, 5.9 Hz), 155.4, 171.7.
- Valerio, R. M., Alewood, P. F., Johns, R. B., Kemp, B. E., *Tetrahedron Lett.*, 2609, (1984).
- Gibson, B. W., Falick, A. M., Burlingame, A. L., Nadasdi, L., Nguyen, A. C. and Kenyon, G. L., *J. Am. Chem. Soc.*, **109**, 5343, (1987).
- Bodanszky, A., Bodanszky, M., Chandramouli, N., Kwei, J. Z., Martinez, J., and Tolle, J. C., *J. Org. Chem.*, **42**, 72, (1980).
- <sup>13</sup>C NMR (CDCl<sub>3</sub>) **11a**: δ 22.0, 22.6, 24.6, 27.6, 27.8, 27.9, 28.2, 29.7 (d, J<sub>PC</sub> 3.3 Hz), 31.9, 41.3, 51.7, 53.2 (d, 5.5 Hz), 54.8, 63.8 (d, 5.5 Hz), 79.0, 80.7, 81.4, 83.2 (d, 7.7 Hz), 155.5, 168.1, 171.0, 172.0, 172.4, 174.8.
- <sup>13</sup>C NMR (CDCl<sub>3</sub>) **11b**: δ 21.8, 22.7, 24.7, 27.4, 27.8, 27.9, 28.2, 31.9, 41.2, 51.7, 53.1 (d, 5.9 Hz), 54.8, 66.7 (d, 5.9 Hz), 79.0, 80.7, 81.4, 155.5, 168.1, 171.0, 172.0, 172.4, 174.7.

(Received in UK 8 March 1988)